OncLive TV

Dr Bal on Ide-cel in R/R Multiple Myeloma

May 18th 2023

Susan Bal, MD, assistant professor, University of Alabama at Birmingham, discusses key efficacy and safety data from the phase 2 KarMMa trial in patients with relapsed/refractory multiple myeloma.

Dr Cole on the Rationale for Investigating Race-based Disparities in Prostate Cancer–Specific Survival

May 18th 2023

Alexander Putnam Cole, MD, discusses the rationale for investigating the magnitude of racial and ethnic disparities in prostate cancer–specific survival in patients undergoing surgery vs radiotherapy.

Dr Das on the Use of Neoadjuvant and Adjuvant Chemoimmunotherapy Regimens in NSCLC

May 18th 2023

Devika Das, MD, MSHQS, discusses the use of neoadjuvant and adjuvant chemoimmunotherapy for patients with resectable non–small cell lung cancer, and emphasizes the importance of multidisciplinary collaboration when incorporating these regimens into treatment approaches.

Dr Gertz on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis

May 17th 2023

Morie A. Gertz, MD, discusses the rationale for the phase 3 AFFIRM-AL trial in patients with amyloid light chain amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.

Dr Suvannasankha on the Potential Mitigation of CRS With REGN5459 in R/R Myeloma

May 17th 2023

Attaya Suvannasankha, MD, discusses addressing the incidence of cytokine release syndrome in a first-in-human phase 1/2 trial for patients with relaped/refractory multiple myeloma.

Dr Muslimani on Unanswered Questions to be Addressed in HER2+ mCRC

May 17th 2023

Alaa Muslimani, MD, discusses unanswered questions in the treatment of patients with metastatic colorectal cancer, highlighting how these unmet needs may be addressed through continued research.

Dr Mina on the Evolution of T-DM1 and T-DXd in HER2+ Breast Cancer

May 17th 2023

Lida A. Mina, MD, discusses the evolution of the antibody-drug conjugates fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine in HER2-positive breast cancer.

Diagnostic Challenges and Clinical Updates in Soft Tissue Sarcomas

May 17th 2023

Advances in the Diagnosis and Treatment of BPDCN

May 17th 2023

Dr Stokes on Radiation Vs Surgery in HPV+ OPSCC

May 16th 2023

William (Bill) Stokes, MD, discusses the use of radiation vs surgery for the treatment of patients with human papillomavirus–related oropharyngeal squamous cell carcinoma.

Dr Tsao on the Investigation of Cabozantinib With Nivolumab and Ipilimumab in RCC

May 16th 2023

Che-Kai Tsao, MD, discusses the investigation of cabozantinib in combination with nivolumab and ipilimumab in patients with renal cell carcinoma.

Dr Goff on the Investigation of Adjuvant Atezolizumab Plus Bevacizumab in HCC

May 16th 2023

Laura Goff, MD, discusses the investigation of adjuvant atezolizumab plus bevacizumab in hepatocellular carcinoma.

Dr Henick on the Use of Neoadjuvant Atezolizumab Plus Chemotherapy in NSCLC

May 16th 2023

Brian Henick, MD, discusses the 3-year updated data from a phase 2 trial investigating treatment with neoadjuvant atezolizumab plus chemotherapy in patients with resectable non–small cell lung cancer.

Dr Habermann on Ongoing Trials in MCL and MZL

May 16th 2023

Thomas M. Habermann, MD, discusses ongoing clinical trials in mantle cell lymphoma and marginal zone lymphoma.

Dr Mascarenhas on First-line Treatment Decisions in Myelofibrosis

May 16th 2023

John Mascarenhas, MD, discusses first-line treatment decisions for patients with myelofibrosis.

​​Dr Byndloss on the Relationship Between Gut Health and the Risk of Developing CRC

May 16th 2023

Mariana X. Byndloss, DVM, PhD, discusses the relationship between the gut microbiome and the risk of developing cancers such as colorectal cancer.

Dr Naumann on the Changing Treatment Landscape in Cervical Cancer

May 16th 2023

R. Wendel Naumann, MD, FACOG, FACS, discusses how the evolution of immunotherapy has changed the treatment landscape for patients with recurrent or metastatic cervical cancer.

Dr Habermann on Data Leading to the Withdrawal of Ibrutinib in MCL

May 16th 2023

Thomas M. Habermann, MD, discusses the data that led to the decision to withdraw the indication for ibrutinib for the treatment of patients with mantle cell lymphoma.

Dr Khalil on the Future Investigations of Immunotherapy in NSCLC

May 15th 2023

Maya Khalil, MD, discusses the future investigations of immunotherapy in non–small cell lung cancer.

Dr Bal on Unmet Needs With CAR T-cell Therapy in Multiple Myeloma

May 15th 2023

Susan Bal, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.